{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:59:18Z","timestamp":1790949558001,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T00:00:00Z","timestamp":1308268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The aims of this pilot study were to assess (1) the safety and tolerability of etanercept in dermatomyositis (DM); (2) the feasibility and safety of a forced prednisone taper; and (3) outcome measures, including those recommended by the International Myositis Assessment Clinical Study (IMACS) group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a randomized, double\u2010blind, placebo\u2010controlled trial of etanercept (50mg subcutaneously weekly) for 52 weeks in DM subjects. Subjects were tapered off prednisone in a standardized schedule as tolerated over the initial 24 weeks of the study. Principal outcomes included adverse events, time from randomization to treatment failure (inability to wean off prednisone on schedule), and average prednisone dosage after week 24.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Sixteen subjects were randomized, 11 to etanercept and 5 to placebo. There were no significant differences in adverse event rates between the treatment groups, although 5 etanercept\u2010treated and 1 placebo\u2010treated subjects developed worsening rash. All 5 subjects receiving placebo were treatment failures (median time to treatment failure 148 days). In contrast, 5 of 11 subjects in the etanercept arm were successfully weaned off prednisone; the median time to treatment failure in this group was 358 days (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0002). The median of the average prednisone dosage after week 24 was 29.2mg\/day in the placebo group and 1.2mg\/day in the etanercept group (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.02). IMACS and other outcome measures demonstrated excellent test\u2013retest reliability (intraclass correlation coefficients 0.79\u20130.99). There was no significant treatment effect on functional outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation:<\/jats:title>\n                    <jats:p>The findings of no major safety concerns and a steroid\u2010sparing effect in our study suggest that further investigation of etanercept as a treatment for DM is warranted. Ann Neurol 2011;<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ana.22477","type":"journal-article","created":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T06:32:08Z","timestamp":1305181928000},"page":"427-436","source":"Crossref","is-referenced-by-count":148,"title":["A randomized, pilot trial of etanercept in dermatomyositis"],"prefix":"10.1002","volume":"70","author":[{"name":"The Muscle Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,6,17]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.169375"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(98)00126-6"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199407000-00008"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2001.5063"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004010051165"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.12.1779"},{"key":"e_1_2_8_9_2","first-page":"4145","article-title":"Expression profiling in untreated juvenile dermatomyositis","volume":"168","author":"Tezak Z","year":"2002","journal-title":"J Immunol"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20019"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000070852"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000079547"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh062"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh226"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh079"},{"key":"e_1_2_8_18_2","first-page":"S193","article-title":"Etanercept is effective in the treatment of polymyositis\/DM which is refractor to conventional therapy including steroids and other disease modifying agents","volume":"43","author":"Constanine K","year":"2000","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000114036"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.142"},{"key":"e_1_2_8_21_2","first-page":"1802","article-title":"Use of etanercept in the treatment of dermatomyositis: a case series","volume":"33","author":"Iannone F","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077974"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225030-00004"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-002-0654-5"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11033"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.11.1031"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07714-0"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.11.1262"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21291"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20349"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.9.1566"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000134675.98525.79"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08711.x"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21016"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119013563"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198903001-00015"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780280513"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00206-1"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.22477","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.22477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:10:02Z","timestamp":1697422202000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.22477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,17]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1002\/ana.22477"],"URL":"https:\/\/doi.org\/10.1002\/ana.22477","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.11510959.12550057","asserted-by":"object"}]},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,17]]}}}